Research and Clinical Trials

Title  

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2

Brief Description  

The purpose of this study is to determine whether antibodies to JC Virus (JCV) may be used to predict whether a patient is at higher or lower risk for developing Progressive Multifocal Leukoencephalopathy (PML)

Who may be Eligible  

Male and female patients who are being treated with Tysabri or are considering treatment with Tysabri

Speciality/Disorder  

MS - Multiple Sclerosis

IRB Number  

CHS1-10-224

Principal Investigator  

Kaufman, Michael

For More Information, Contact  Joyce  , Pitner
Phone:  (704) 446-1349  Fax:  (704) 446-6208  
Email:  joyce.pitner@atriumhealth.org
Address:1010 Edgehill Road North Charlotte, NC 28207